Johnson & Johnson Vision to Acquire TearScience

August 4, 2017: By Jon Swedien

JJV logo x300Johnson & Johnson Vision announced Aug. 4 that it has signed a definitive agreement to acquire TearScience, a Morrisville, North Carolina, company that develops and markets products for meibomian gland dysfunction (MGD), an underlying cause of dry eye disease.

Financial terms were not disclosed.

The deal is expected to close by the end of the year, J&J Vision said. Following the closing, sales will be reported in J&J’s Medical Devices segment, under Vision Care, the company said. J&J Vision’s ophthalmic surgery division is located in Santa Ana, California.

TearScience received FDA clearance in July 2011 for its LipiFlow system, an office-based approach to image meibomian glands and treat MGD. The company sells its products in the US and major markets globally, J&J Vision said.

The TearScience acquisition strengthens J&J Vision’s portfolio, allowing it to provide a critical solution to its optometric and ophthalmic customers who serve dry eye patients, company officials said.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023